Rob, L., Cibula, D., Knapp, P., Mallmann, P., Klat, J., Minar, L., Bartos, P., Chovanec, J., Valha, P., Pluta, M., Novotny, Z., Spacek, J., Melichar, B., Kieszko, D., Fucikova, J., Hrnciarova, T., Korolkiewicz, R. P., Hraska, M., Bartunkova, J. and Spisek, R. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. Journal for ImmunoTherapy of Cancer. 2022; 10(1), p. e003190. doi: 10.1136/jitc-2021-003190